Cargando…

Remdesivir in Treatment of COVID-19: A Systematic Benefit–Risk Assessment

INTRODUCTION: There is a need to identify effective, safe treatments for COVID-19 (coronavirus disease) rapidly, given the current, ongoing pandemic. A systematic benefit–risk assessment was designed and conducted to examine the benefit–risk profile of remdesivir in COVID-19 patients compared with s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davies, Miranda, Osborne, Vicki, Lane, Samantha, Roy, Debabrata, Dhanda, Sandeep, Evans, Alison, Shakir, Saad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255634/ https://www.ncbi.nlm.nih.gov/pubmed/32468196 http://dx.doi.org/10.1007/s40264-020-00952-1

Ejemplares similares

Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment
por: Osborne, Vicki, et al.
Publicado: (2020)

Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management
por: Osborne, Vicki, et al.
Publicado: (2020)

A Systematic Review of Flurbiprofen 8.75 mg Dose and Risk of Haemorrhagic Events
por: Dhanda, Sandeep, et al.
Publicado: (2021)

Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care: an observational cohort study
por: Evans, Alison, et al.
Publicado: (2020)

Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
por: Evans, Alison, et al.
Publicado: (2020)

Observational assessment of safety in seroquel (OASIS): a specialist cohort event monitoring (SCEM) study in England
por: Osborne, Vicki, et al.
Publicado: (2020)

Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK?
por: Dhanda, Sandeep, et al.
Publicado: (2022)

The Role of the Contextual Cohort to Resolve Some Challenges and Limitations of Comparisons in Pharmacoepidemiology
por: Osborne, Vicki, et al.
Publicado: (2021)

Benefit-risk assessment for remdesivir in COVID-19
Publicado: (2020)

How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine
por: Shakir, Saad, et al.
Publicado: (2020)

Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination
por: Lane, Samantha, et al.
Publicado: (2022)

Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature
por: Lane, Samantha, et al.
Publicado: (2022)

What Is the Difference Between Observed Association and Causal Association, Signals and Evidence? Examples Related to COVID-19
por: Osborne, Vicki, et al.
Publicado: (2021)

Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?
por: Vitiello, Antonio, et al.
Publicado: (2021)

Remdesivir use in severe renal impairment: benefits outweigh risks
Publicado: (2021)

Assessing Case Fatality on Cases of Thrombosis with Concurrent Thrombocytopenia Following COVID-19 Vaccine AstraZeneca (Vaxzevria) in the United Kingdom: A Review of Spontaneously Reported Data
por: Lane, Samantha, et al.
Publicado: (2022)

Correction to: Assessing Case Fatality on Cases of Thrombosis with Concurrent Thrombocytopenia Following COVID-19 Vaccine AstraZeneca (Vaxzevria) in the United Kingdom: A Review of Spontaneously Reported Data
por: Lane, Samantha, et al.
Publicado: (2022)

Indicators of Drug-Seeking Aberrant Behaviours: The Feasibility of Use in Observational Post-Marketing Cohort Studies for Risk Management
por: Layton, Deborah, et al.
Publicado: (2014)

Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012
por: Lane, Samantha, et al.
Publicado: (2018)

Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis
por: Bansal, Vikas, et al.
Publicado: (2021)

Assessing the evidence on remdesivir
por: Núñez, Isaac, et al.
Publicado: (2021)

Assessing the evidence on remdesivir
por: Trøseid, Marius, et al.
Publicado: (2021)

Protocol: Benefits and harms of remdesivir for COVID-19 in adults: A systematic review with meta-analysis
por: Paludan-Müller, Asger Sand, et al.
Publicado: (2021)

Utilisation and Safety of Polyethylene Glycol 3350 With Electrolytes in Children Under 2 Years: A Retrospective Cohort
por: Roy, Debabrata, et al.
Publicado: (2021)

Addendum to Systematic Review of Remdesivir for the Treatment of COVID-19
por: Musa, Arif, et al.
Publicado: (2020)

Remdesivir
por: Bakheit, Ahmed H., et al.
Publicado: (2023)

Safety of Intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) in Children and Adolescents: A Pilot Prospective Cohort Study in England
por: McNaughton, Rhian, et al.
Publicado: (2016)

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
por: Williamson, Brandi N., et al.
Publicado: (2020)

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
por: Williamson, Brandi N., et al.
Publicado: (2020)

Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit
por: Sun, Duxin
Publicado: (2020)

Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature
por: Musa, Arif, et al.
Publicado: (2020)

Correction to: Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Additional Benefit
por: Sun, Duxin
Publicado: (2020)

Long-term survival benefit of male and multimorbid COVID-19 patients with 5-day remdesivir treatment
por: Polivka, Lorinc, et al.
Publicado: (2022)

Remdesivir in Breastfeeding
por: Sadati, Elham, et al.
Publicado: (2022)

Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis
por: Rezagholizadeh, Afra, et al.
Publicado: (2021)

Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis
por: Lee, Todd C., et al.
Publicado: (2022)

Remdesivir for the Treatment of Covid-19 — Final Report
por: Beigel, John H., et al.
Publicado: (2020)

Remdesivir: Infusion site reaction following extravasation of remdesivir: case report
Publicado: (2021)

Past, Present, and Future of Remdesivir: An Overview of the Antiviral in Recent Times
por: Choudhury, Shouvik, et al.
Publicado: (2020)

Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients
por: Coelho, Luís, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d1j17v1ct83m0h3fge7hv3a866